Clinical Trials Logo

Clinical Trial Summary

The purpose of this clinical trial is to determine whether there is any effect on the antibiotic, ciprofloxacin when taken before and after administration of a 3-dose series of BioThrax® (Anthrax Vaccine Adsorbed or AVA). This study will be conducted in the United States (US) in 154 healthy male and female volunteer subjects ages 18 to 45. The duration of study participation for each subject will be approximately 76 days (approximately 2.5 months)


Clinical Trial Description

BioThrax is the only FDA-licensed vaccine for the prevention of anthrax infection. This is a randomized, open-label, Phase 2, multi-center trial to investigate the potential interactions of ciprofloxacin and BioThrax. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01753115
Study type Interventional
Source Emergent BioSolutions
Contact
Status Completed
Phase Phase 2
Start date December 2012
Completion date August 2013

See also
  Status Clinical Trial Phase
Completed NCT00114621 - Anthrax Vaccine Clinical Trials Phase 1
Recruiting NCT00050310 - Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
Completed NCT01453907 - Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers Phase 1
Completed NCT01491607 - Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults Phase 3
Completed NCT03518125 - BARDA Securing Anthrax Immunity For the Elderly Phase 2
Completed NCT04660201 - Anthrax AV7909 Liquid vs Lyophilized Phase 1
Completed NCT04320485 - Evaluation of the Clinical Specificity of the Active Anthrax Detectâ„¢ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)
Recruiting NCT06365073 - A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax
Completed NCT03877926 - VELOCITY: An Anthrax Vaccine Clinical Study Phase 3
Completed NCT03498027 - Febrile Whole Blood Specimen Collection and Testing
Terminated NCT00964834 - Ph1 Study of Valortim and Doxycycline in Humans Phase 1
Completed NCT00063843 - Anthrax-rPA: Safety, Tolerability, Immunogenicity Phase 1
Completed NCT01624532 - A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Phase 2
Completed NCT04148118 - A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults Phase 1
Terminated NCT05672875 - Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System
Completed NCT01770743 - A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels Phase 2
Completed NCT01867957 - Efficacy and Safety of Anthrax Vaccine, GC1109 Phase 1
Completed NCT00845650 - Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) Phase 1/Phase 2
Completed NCT00031291 - Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin N/A
Not yet recruiting NCT03569514 - Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax